Investor Relations

Company Overview

Assembly Biosciences, Inc. (Nasdaq: ASMB) is a public biotechnology company advancing a new class of oral biologic drugs for addressing the gut microbiome and novel approaches to discovering drugs for the treatment of hepatitis B virus (HBV) infection.

Stock Quote

NASDAQ: ASMB
41.70
- 2.29 (-5.21%)
2:18 PM ET on Dec 12, 2017
Delayed at least 20 minutes.

Stock Chart

Press Releases

Events & Presentations

November 15, 2017 at 11:20 AM UK

Investor Contact

investors@assemblybio.com